Synthetic Biologics Inc (SYN) Sees Large Decline in Short Interest

Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,229,063 shares, a decrease of 2.6% from the January 12th total of 4,341,664 shares. Currently, 3.7% of the shares of the company are short sold. Based on an average daily volume of 659,108 shares, the days-to-cover ratio is presently 6.4 days.

Several equities research analysts have recently commented on SYN shares. BidaskClub cut Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Zacks Investment Research cut Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th.

Synthetic Biologics (NYSEAMERICAN:SYN) traded down $0.01 during trading on Friday, hitting $0.41. The stock had a trading volume of 1,061,934 shares, compared to its average volume of 840,058. Synthetic Biologics has a twelve month low of $0.37 and a twelve month high of $1.05. The stock has a market capitalization of $56.58, a PE ratio of -1.86 and a beta of 1.08.

A hedge fund recently raised its stake in Synthetic Biologics stock. Virtu Financial LLC lifted its stake in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 256.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 299,577 shares of the company’s stock after purchasing an additional 215,440 shares during the quarter. Virtu Financial LLC owned about 0.23% of Synthetic Biologics worth $152,000 at the end of the most recent quarter.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/09/synthetic-biologics-inc-syn-sees-large-decline-in-short-interest.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply